Abstract:Xue-Qing Guan, 1 Chuan-He Wang, 1 Peng Cheng, 1 Ling-Yu Fu, 2 Qi-Jun Wu, 3– 5 Gong Cheng, 1 Lin Guan, 1 Zhi-Jun Sun 1 1 Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, 110021, People's Republic of China; 2 Department of Clinical Epidemiology and Evidence-Based Medicine, The First Affiliated Hospital, China Medical University, Shenyang, 110021, People's Republic of China; 3 Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, 110021, People's Republic of China; 4 Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110021, People's Republic of China; 5 Clinical Research Center, Shengjing Hospital of China Medical University, Shenyang, 110021, People's Republic of China Correspondence: Zhi-Jun Sun, Department of Cardiology, Shengjing Hospital of China Medical University, No. 39 of Huaxiang Road, Tiexi District, Shenyang, 110021, People's Republic of China, Tel +86 02496615, Email Although empagliflozin has been recommended for individuals with heart failure, its effects on heart failure with preserved ejection fraction (HFpEF) remain uncertain from a physiopathological standpoint. The metabolites produced by gut microbiota have been shown to have a crucial role in the development of heart failure. Sodium-glucose cotransporter-2 inhibitors (SGLT2) have been shown to change the make-up of the gut microbiota in rodent studies. There is mixed evidence from similar studies investigating whether or not SGLT2 can affect the microbiota in the human gut. This trial is a pragmatic, randomized, open-label controlled study with empagliflozin as an intervention. We will enroll 100 patients with HFpEF and randomly assign them to one of two groups to receive either empagliflozin or a placebo. Patients in the Empagliflozin group will be given 10 mg of the drug daily, while those in the Control group will not be given empagliflozin or any other SGLT2. The purpose of the trial is to validate the changes that occur in gut microbiota in patients with HFpEF who take empagliflozin and to investigate the function of gut microbiota and their metabolites in the process. Keywords: derived metabolite, gut microbiota, heart failure, HF, myocardial fibrosis, SGLT2, short-chain fatty acids, SCFAs, sodium-glucose cotransporter-2 inhibitor Heart failure (HF) is a complex clinical disease characterized by symptoms and indications caused by any anatomical or functional impairment of ventricular filling or blood ejection. 1 As one of the major cardiac disorders, HF has a significant morbidity and mortality rate around the world. According to data from a multicenter observational study, the combined endpoint of mortality or HF hospitalization after one year was 36% for acute heart failure (AHF) and 14.5% for chronic heart failure (CHF). 2 There were 1.2 million heart failure hospitalizations in the United States in 2017, involving 924,000 patients. This represents a 26% increase over the last decade, and the figure is expected to rise more in the future. 1 Heart failure can be categorized into several phenotypes based on the left ventricular ejection fraction (LVEF), with HFpEF accounting for more than half of all patients. 3 HFpEF is a complex biological process that includes systemic inflammation, epicardial adipose tissue buildup, cardiac fibrosis, and vascular dysfunction, among other metabolic pathways. 4–6 However, the mechanisms and therapeutic strategies for it require additional experimental data. 7 Intestinal flora is a complex collection of microbial communities that are intimately linked to the human body and participate in a variety of biological processes. 8 Patients with heart failure frequently have decreased cardiac output as well as peripheral circulation congestion. In this circumstance, intestinal ischemia and edema cause a disruption in gut flora, resulting in an overproduction of inflammatory agents and toxic metabolites, which accelerates the HF process. 9–11 However, new evidence suggests that gut metabolites play a role in various HF pathways. Some of them (such as SCFAs) have potential protective effects, whereas others (uremic toxins) have the inverse effect. 12 Empagliflozin, a novel type of hypoglycemic medication, is an SGLT2 that blocks glucose reabsorption by the kidneys. As a result, more glucose is excreted in the urine, decreasing blood glucose levels. However, multiple research have revealed other biological effects of SGLT2. SGLT2 has been shown in animal models to reduce sodium consumption, inhibit NO production, enhance cardiac energy metabolism, and regulate -Abstract Truncated-

Empagliflozin ameliorates atherosclerosis via regulating the intestinal flora

Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model

Empagliflozin attenuates liver fibrosis in high‐fat diet/streptozotocin‐induced mice by modulating gut microbiota

The effect of canagliflozin on gut microbiota and metabolites in type 2 diabetic mice

Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis

Empagliflozin alleviates neuroinflammation by inhibiting astrocyte activation in the brain and regulating gut microbiota of high-fat diet mice

Empagliflozin Modify Gut Microbiota in Db/db Mice Correlating with the Improvement of Glucose and Lipid Metabolism

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice

Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease

Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice

Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism

Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

SGLT-2 inhibition by empagliflozin has no effect on experimental arterial thrombosis in a murine model of low-grade inflammation

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease

Effects of Empagliflozin on Gut Microbiota in Heart Failure with a Preserved Ejection Fraction: The Design of a Pragmatic Randomized, Open-Label Controlled Trial (EMPAGUM)

Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy

Empagliflozin treatment differentially modifies visceral and subcutaneous adipose tissue lipidomes and pro-inflammatory cytokines in zucker fatty diabetic rats